Kaletra comes up short in COVID-19 study

30 June 2020

There is no meaningful mortality benefit of the antiviral combination of lopinavir and ritonavir, an HIV drug marketed by AbbVie (NYSE: ABBV) as Kaletra, in patients hospitalized with COVID-19.

That is the conclusion of the Steering Committee for the RECOVERY trial being run at the University of Oxford (pictured), the same study that has identified the effectiveness of the off-patent medicine dexamethasone in saving lives.

Peter Horby, professor of emerging infectious diseases and global health in the Nuffield Department of Medicine, University of Oxford, and chief investigator for the trial, said: ‘Today we release the third set of results from the RECOVERY trial. These preliminary results show that for patients hospitalized with COVID-19 and not on a ventilator, lopinavir-ritonavir is not an effective treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK